Patrick Daly

Urban Health Today

Recently, researchers noted that no studies directly compare bortezomib-lenalidomide-dexamethasone (VRd) and daratumumab plus bortezomib-thalidomide-dexamethasone (D-VTd) in patients with multiple myeloma (MM), both of which are guideline-recommended induction therapy regimens.
The study’s authors ultimately supported using a quadruplet regimen with a CD38 monoclonal antibody over the triplet regimen as front-line induction therapy to achieve adequate disease control among transplant-eligible patients with MM. Findings from the study were published in <a href="https://www.bloodresearch.or.kr/journal/view.html?doi=10.5045/br.2023.2023005#n" target="_blank" rel="noopener">Blood Research</a>.
<h3>D-VTd Versus VRd for Disease Control</h3>
The study included 37 patients treated with VRd and 43 treated with D-VTd between November 2020 and December 2021. All patients were over 18 years old and underwent autologous stem cell transplantation after induction therapy. Responses and safety outcomes were compared between the groups.
Researchers reported the following response outcomes per group:
<table border="1">
<tbody>
<tr>
<td style="text-align: center;" width="208"></td>
<td style="text-align: center;" width="208">VRd</td>
<td style="text-align: center;" width="208">D-VTd</td>
</tr>
<tr>
<td style="text-align: center;" width="208">Stringent complete remission</td>
<td style="text-align: center;" width="208">10.8%</td>
<td style="text-align: center;" width="208">9.3%</td>
</tr>
<tr>
<td style="text-align: center;" width="208">Complete remission</td>
<td style="text-align: center;" width="208">21.6%</td>
<td style="text-align: center;" width="208">34.9%</td>
</tr>
<tr>
<td style="text-align: center;" width="208">Very good partial response</td>
<td style="text-align: center;" width="208">35.1%</td>
<td style="text-align: center;" width="208">48.8%</td>
</tr>
<tr>
<td style="text-align: center;" width="208">Partial response</td>
<td style="text-align: center;" width="208">32.4%</td>
<td style="text-align: center;" width="208">4.2%</td>
</tr>
</tbody>
</table>
&nbsp;
In addition, 67.6% of patients in the VRd group achieved a very good partial response or better compared with 90.5% of patients in the D-VTd group (P=.004).
After transplantation, 68.6% of patients in the VRd group achieved stringent complete remission or complete response compared with 90.5% of patients in the D-VTd group (P=.016). Lastly, VRd was associated with an increased incidence of skin rash events (P=.044), though the authors noted no other significant differences in adverse events.
To conclude, the authors suggested, “Our study supports the use of a front-line quadruplet induction regimen containing a CD38 monoclonal antibody for transplant-eligible patients with newly diagnosed MM.”
Related: <a href="https://urbanhealthtoday.com/post/can-mirnas-predict-mm-treatment-response">Can miRNAs Predict MM Treatment Response?</a>

Urban Health Today Editors

Dr. Gregg Sylvester on Why 2024-2025 is "one of the worst" Flu Seasons

Public Health

Lou Portero

Better Interpersonal Care Boosts HIV Patient Engagement, Study Finds

Type 2 Diabetes Remission Achievable with Primary Care-Led Weight Management

Obesity

Latest News

Comparing Induction Regimens for Multiple Myeloma

Multiple Myeloma

Researchers supported the use of D-VTd over VRd for induction therapy in multiple myeloma after comparing outcome data.

About Us

Editorial Policy

Contributors & Partners

Contact Us

eNewsletters

Work With Us

Advertising

Career Center

GU Oncology Now

Blood Cancers Today

Cancer Nursing Today

DocWire News

MashupMD

Food Allergy Roundtable Discussions

Allergy

Blood Cancers

— Multiple Myeloma

Breast Cancer

Colorectal Cancer

Pancreatic Cancer

Prostate Cancer

Cancer

Diabetes

Gastroenterology

Heart Failure

Heart Disease Prevention

Heart Health

— Alzheimer’s Disease

Neurology

Autoimmune Disease

Infectious Diseases

Pediatrics

Sickle Cell Disease

Digital Health

Dermatology

Pulmonology

Video Insights

Workforce News

More

Gynecologic Cancer

Heart Disease in Women

Menopause

Reproductive Health

Women’s Neurology

Well Woman Today

Roundtables

Podcasts

Conferences

Viewpoints

Subscribe